PMID- 37909991
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231102
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 11
DP  - 2023 Nov
TI  - Renal Cell Cancer - Insights in Drug Resistance Mechanisms.
PG  - 4781-4792
LID - 10.21873/anticanres.16675 [doi]
AB  - Renal cell carcinoma (RCC) is the prevalent form of kidney cancer in adults, with 
      clear cell renal carcinoma (ccRCC) being the predominant subtype. While surgical 
      resection remains the primary curative approach for localized RCC, a significant 
      number of patients encounter disease relapse. The advent of targeted therapies, 
      including tyrosine kinase inhibitors (TKI), mammalian target of rapamycin (mTOR) 
      inhibitors, and immune checkpoint inhibitors, has revolutionized the treatment of 
      metastatic RCC. However, despite therapeutic advancements, the emergence of 
      resistance poses a significant challenge. Resistance mechanisms in RCC involve 
      the disruption of hypoxia pathways, activation of the PI3K/AKT/mTOR pathway, and 
      increased expression of alternate proangiogenic factors. Furthermore, the 
      sequestration of TKI within lysosomes contributes to reduced drug effectiveness 
      and development of resistance. Current research is focused on overcoming 
      resistance by identifying predictive biomarkers for treatment efficacy, 
      developing novel variations of existing therapies that target alternative 
      signalling pathways, and exploring combination therapy approaches. The objective 
      of this review article was to provide a comprehensive assessment of resistance 
      mechanisms to systemic therapies and explore emerging treatment strategies for 
      RCC.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Aweys, Halima
AU  - Aweys H
AD  - Department of Medical Oncology, Medway NHS Foundation Trust, Kent, U.K.
FAU - Lewis, Deisha
AU  - Lewis D
AD  - Department of Medical Oncology, Medway NHS Foundation Trust, Kent, U.K.
FAU - Sheriff, Matin
AU  - Sheriff M
AD  - Department of Urology, Medway NHS Foundation Trust, Kent, U.K.
FAU - Rabbani, Rukhshana Dina
AU  - Rabbani RD
AD  - Department of Medical Oncology, Medway NHS Foundation Trust, Kent, U.K.
FAU - Lapitan, Patricia
AU  - Lapitan P
AD  - School of Medical Sciences, The University of Manchester, Manchester, U.K.
AD  - Cancer Institute, Faculty of Medical Sciences, University College London, London, 
      U.K.
AD  - Division of Genetics and Epidemiology, The Institute of Cancer Research, Surrey, 
      U.K.
FAU - Sanchez, Elisabet
AU  - Sanchez E
AD  - Department of Medical Oncology, Medway NHS Foundation Trust, Kent, U.K.
FAU - Papadopoulos, Vasileios
AU  - Papadopoulos V
AD  - Department of Urology, Medway NHS Foundation Trust, Kent, U.K.
FAU - Ghose, Aruni
AU  - Ghose A
AD  - Department of Medical Oncology, Medway NHS Foundation Trust, Kent, U.K.
AD  - Department of Medical Oncology, Barts Cancer Centre, St. Bartholomew's Hospital, 
      Barts Health NHS Trust, London, U.K.
AD  - Department of Medical Oncology, Mount Vernon Cancer Centre, East and North 
      Hertfordshire NHS Trust, London, U.K.
AD  - Immuno-Oncology Clinical Network, London, U.K.
FAU - Boussios, Stergios
AU  - Boussios S
AD  - Department of Medical Oncology, Medway NHS Foundation Trust, Kent, U.K.; 
      stergiosboussios@gmail.com.
AD  - Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, 
      King's College London, London, U.K.
AD  - Kent Medway Medical School, University of Kent, Kent, U.K.
AD  - AELIA Organization, Thessaloniki, Greece.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - EC 2.7.1.- (Phosphatidylinositol 3-Kinases)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Carcinoma, Renal Cell/drug therapy/genetics
MH  - Phosphatidylinositol 3-Kinases
MH  - *Kidney Neoplasms/drug therapy/genetics
MH  - Immune Checkpoint Inhibitors
MH  - TOR Serine-Threonine Kinases/genetics
OTO - NOTNLM
OT  - Renal cell cancer
OT  - mechanisms of resistance
OT  - overcoming resistance
OT  - review
OT  - treatment
EDAT- 2023/11/01 12:44
MHDA- 2023/11/02 12:46
CRDT- 2023/11/01 10:44
PHST- 2023/08/10 00:00 [received]
PHST- 2023/09/14 00:00 [revised]
PHST- 2023/09/20 00:00 [accepted]
PHST- 2023/11/02 12:46 [medline]
PHST- 2023/11/01 12:44 [pubmed]
PHST- 2023/11/01 10:44 [entrez]
AID - 43/11/4781 [pii]
AID - 10.21873/anticanres.16675 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Nov;43(11):4781-4792. doi: 10.21873/anticanres.16675.